$11.02
+0.14 (+1.29%)
Open$11.07
Previous Close$10.88
Day High$11.38
Day Low$10.61
52W High$16.76
52W Low$9.85
Volume—
Avg Volume106.3K
Market Cap396.27M
P/E Ratio—
EPS$-1.11
SectorBiotechnology
Analyst Ratings
Strong Buy
13 analysts
Price Target
+143.8% upside
Current
$11.02
$11.02
Target
$26.87
$26.87
$21.20
$26.87 avg
$38.04
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 792.56M | 838.23M | 726.24M |
| Net Income | 29.18M | 25.09M | 21.12M |
| Profit Margin | 3.7% | 3.0% | 2.9% |
| EBITDA | 33.32M | 33.92M | 33.30M |
| Free Cash Flow | 24.79M | 28.65M | 30.31M |
| Rev Growth | +7.9% | +14.3% | -7.3% |
| Debt/Equity | 0.15 | 0.16 | 0.16 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $265.21 | +0.28% | 74.0 | 466.74B |
| AMGN | Amgen Inc | $410.24 | +4.34% | 23.7 | 207.25B |
| GILD | Gilead Sciences Inc | $152.67 | +1.40% | — | 187.10B |
| VRTX | Vertex Pharmaceuticals Inc | $514.99 | +0.84% | 29.7 | 130.64B |
| REGN | Regeneron Pharmaceuticals | $803.90 | +0.72% | 18.6 | 80.58B |
| ALNY | Alnylam Pharmaceuticals Inc | $251.65 | +3.00% | 40.0 | 32.33B |